MedTrace Logo

Clinical Performance of the Globe® Mapping and Ablation System for the Treatment of Atrial Fibrillation

NCT04954911 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2023-09-18

No results posted yet for this study

Summary

This is an observational, multicentre, prospective, post-market product registry for participants with AF for whom ablation by the commercially available Globe Mapping and Ablation System was indicated before enrolment into the registry. The aim of the registry is to confirm the clinical performance and safety of the Globe Mapping and Ablation System in a real-life setting.

Conditions

Sponsors & Collaborators

  • Kardium Inc.

    lead INDUSTRY

Principal Investigators

  • Herz- und Diabeteszentrum NRW · Klinik für Elektrophysiologie/Rhythmologie Herz- und Diabeteszentrum NRW Universitätsklinik der Ruhr-Universität Bochum

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-02
Primary Completion
2023-05-23
Completion
2023-05-23

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04954911 on ClinicalTrials.gov